Navigation ABOUT CAMURUS CEO statement Management team Board of directors Career Code of conduct PRODUCTS PIPELINE TECHNOLOGIES FluidCrystal® injection depot FluidCrystal® topical bioadhesive FluidCrystal® nanoparticles INVESTORS The share Shareholders Analyst Coverage General meetings Corporate governance Press releases Events & presentations Financial reports Subscription IR contact Prospectus MEDIA CONTACT ENGLISH Swedish German ABOUT CAMURUS CEO statement Management team Board of directors Career Code of conduct PRODUCTS PIPELINE TECHNOLOGIES FluidCrystal® injection depot FluidCrystal® topical bioadhesive FluidCrystal® nanoparticles INVESTORS The share Shareholders Analyst Coverage General meetings Corporate governance Press releases Events & presentations Financial reports Subscription IR contact Prospectus MEDIA CONTACT ENGLISH Swedish German TECHNOLOGIES FluidCrystal® – smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. TECHNOLOGIES FluidCrystal® – smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. FluidCrystal® injection depot Camurus’ FluidCrystal® injection depot is designed to provide treatment efficacy over extended periods – from days to months – with a single injection. It has the potential to reduce the burden of daily medication while increasing adherence to therapy. FluidCrystal® is suitable for biological peptides as well as small molecules. The FluidCrystal® injection depot comprises a lipid-based liquid with a dissolved active ingredient that can easily be injected subcutaneously using a conventional syringe with a thin needle. Upon contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which effectively encapsulates the active ingredient. The drug compound is slowly released as the liquid crystalline matrix gradually degrade in the tissue and the release can be controlled from several days to weeks or months depending on the composition. The system’s simplicity, including a spontaneous self-association to a functional structure in the body, eliminates complicated manufacturing procedures and the need for mixing prior to administration. Medicines based on the FluidCrystal® injection depot has the potential to be administered by the patients themselves or by healthcare professionals, without time-consuming and complicated reconstitution procedures. The long-acting drug release aims to reduce the patient’s burden of administering medication daily, improve the adherence to and results of the treatment, and improve the patient’s quality of life. Key attributes • Easy and convenient administration • Improved treatment adherence • Adapted to prefilled syringes and autoinjectors • Long-acting drug release • Small injection volume with a thin needle • Good safety profile • Manufacturing by standard processes 1. Subcutaneous injection of lipid-based formulation 2. Liquid crystal gel formation on water absorption (w) 3. Slow release of drug compound (D), biodegradation of depot FluidCrystal® topical bioadhesive FluidCrystal® topical bioadhesive is a liquid product that forms a bioadhesive film when applied to body tissues. The film acts as an invisible patch, slowly and accurately releasing the active ingredient for the treatment, systemically or locally. It also acts as a protective barrier for sensitive and inflamed tissues. The bioadhesive formulation is suitable for the prolonged local release of active ingredients on the skin and on the mucous membranes of for example the mouth, nose, and throat. The formulation is applied topically as a low-viscosity liquid. It then spreads, absorbing minute amounts of water and transforming into a thin bioadhesive liquid crystalline film. FluidCrystal® topical bioadhesive products can be administered using metered dose pumps, tubes, and other primary packaging forms for liquids. The commercially available product episil® is based on the FluidCrystal® topical bioadhesive technology. Key attributes • Strong adhesion and retention at biological surfaces • Protects sensitive tissue • Relieves topical pain • High solubilizing capacity for active ingredients • Extended local or systemic release of pharmaceutical substances • Good local tolerability • Manufacturing by standard processes FluidCrystal® nanoparticles FluidCrystal® nanoparticles can resolve bioavailability issues for water and lipid-soluble pharmaceuticals or biodegradation-sensitive drugs, such as peptides and proteins. FluidCrystal® nanoparticles are usually water-based and comprise a stable emulsion of nanoparticles with a liquid crystalline structure. Investigational medicinal products based on this technology are administered either parenterally via injections, or as a liquid sprayed onto the skin or mucous membranes. Key attributes • Prolonged systemic drug circulation (parenteral administration) • Enhanced delivery over mucosal and skin surfaces (topical administration) • Protection of sensitive drug substances • High solubilization capacity of drug substances • Good systemic and local tolerability demonstrated in pre-clinical and clinical trials Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Sölvegatan 41 A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email Addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations ir@camurus.com About Camurus Presentations Pipeline Products Technologies Investors Career Legal notice Privacy Contact IR contact By continuing to use the site, you agree to the use of cookies. more information Accept The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Close